Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis
Authors:
- 1 June 2009
- journal article
- research article
- Published by Wiley in International Journal of Dermatology
- Vol. 48 (6) , 653-658
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- Long-term treatment of plaque psoriasis with efalizumab: an Italian experienceBritish Journal of Dermatology, 2007
- The Greek experience with efalizumab in psoriasis from a University Dermatologic HospitalBritish Journal of Dermatology, 2007
- An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic optionsExpert Opinion on Pharmacotherapy, 2007
- Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)Journal of the American Academy of Dermatology, 2007
- Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risksBritish Journal of Dermatology, 2005
- Modern modified ‘ultra’ Goeckerman therapy: A PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapiesJournal of Dermatological Treatment, 2005
- Novel pharmacological approaches in the treatment of psoriasisJournal of the European Academy of Dermatology and Venereology, 2004
- Psoriasis causes as much disability as other major medical diseasesJournal of the American Academy of Dermatology, 1999
- Cost-effectiveness of Methotrexate and Goeckerman Therapy: A Flawed AnalysisArchives of Dermatology, 1999
- TREATMENT OF PSORIASISArchives of Dermatology and Syphilology, 1931